Filtered By:
Condition: Depression
Drug: Prozac

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 140 results found since Jan 2013.

Efficacy of Fluoxetine for Post-Ischemic Stroke Depression in Tanzania
Post-stroke fluoxetine trials are primarily conducted in high-income countries. We characterize post-ischemic stroke depression in fluoxetine-treated and -untreated study participants in urban Tanzania.
Source: Journal of Stroke and Cerebrovascular Diseases - November 2, 2021 Category: Neurology Authors: Dylan R. Rice, Kigocha Okeng'o, Emmanuel Massawe, Seif Ismail, Notburga A. Mworia, Faraja Chiwanga, Boniface Kapina, Michael Wasserman, Farrah J. Mateen Source Type: research

Treating post-stroke depression with Xingnao Jieyu capsules or fluoxetine
The occurrence of post-stroke depression results from the effects of biological, psychological, and social factors, likely involving neurotransmitters, neuroendocrine effects, nerve anatomy, neurotrophic factors, neural regeneration, inflammatory reactions, and social psyche factors. Synaptotagmin promotes neurotransmitter release, regulates the transfer of synaptic vesicle to synaptic active zones, and is a key factor in information transfer among neurons. The Xingnao Jieyu capsule has been shown to effectively relieve neurologic impairments and lessen depression...
Source: Health News from Medical News Today - August 16, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
CONCLUSIONS: We found no reliable evidence that SSRIs should be used routinely to promote recovery after stroke. Meta-analysis of the trials at low risk of bias indicate that SSRIs do not improve recovery from stroke. We identified potential improvements in disability only in the analyses which included trials at high risk of bias. A further meta-analysis of large ongoing trials will be required to determine the generalisability of these findings. PMID: 31769878 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - November 25, 2019 Category: General Medicine Authors: Legg LA, Tilney R, Hsieh CF, Wu S, Lundström E, Rudberg AS, Kutlubaev MA, Dennis M, Soleimani B, Barugh A, Hackett ML, Hankey GJ, Mead GE Tags: Cochrane Database Syst Rev Source Type: research

Podcast: Selective serotonin reuptake inhibitors for stroke recovery
Stroke is a major cause of death and disability across the world, with many reviews from the Cochrane Stroke Group providing evidence on the effects of treatments and rehabilitation interventions. In November 2019, the Group published their update of their review of selective serotonin reuptake inhibitors and we asked lead author, Gillian Mead from the University of Edinburgh in Scotland, to tell us more.Stroke is a common cause of disability in the community. Although there have been major advances in the care of stroke patients over the last few years, many survivors are still left with physical disability, such as weakn...
Source: Cochrane News and Events - February 26, 2020 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence
ConclusionIn addition to the need of comprehensive‐clinical evidence, further elucidation of the beneficial mechanisms whereby SSRIs may improve structural and functional recovery from ischemic‐brain damage is needed to form a basis for translation into clinical practice. Several clinical studies have indicated that selective serotonin reuptake Inhibitors (SSRIs) administered after acute ischemic stroke can improve clinical recovery independently of depression. However, data from confirmatory trials in large study populations are lacking and the underlying mechanisms are incompletely understood. This review summarizes...
Source: Brain and Behavior - September 1, 2015 Category: Neurology Authors: Timo Siepmann, Ana Isabel Penzlin, Jessica Kepplinger, Ben Min‐Woo Illigens, Kerstin Weidner, Heinz Reichmann, Kristian Barlinn Tags: Review Source Type: research

The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials
DiscussionIf fluoxetine is safe and effective in promoting functional recovery, it could be rapidly, widely and affordably implemented in routine clinical practice and reduce the burden of disability due to stroke.Trial registrationFOCUS: ISRCTN83290762 (23/05/2012), AFFINITY: ACTRN12611000774921 (22/07/2011). EFFECTS: ISRCTN13020412 (19/12/2014).
Source: Trials - August 20, 2015 Category: Journals (General) Authors: Gillian MeadMaree HackettErik LundströmVeronica MurrayGraeme HankeyMartin Dennis Source Type: research

Up-regulation of serotonin receptor 2B mRNA and protein in the peri-infarcted area of aged rats and stroke patients.
Authors: Buga AM, Ciobanu O, Bădescu GM, Bogdan C, Weston R, Slevin M, DiNapoli M, Popa-Wagner A Abstract Despite the fact that a high proportion of elderly stroke patients develop mood disorders, the mechanisms underlying late-onset neuropsychiatric and neurocognitive symptoms have so far received little attention in the field of neurobiology. In rodents, aged animals display depressive symptoms following stroke, whereas young animals recover fairly well. This finding has prompted us to investigate the expression of serotonin receptors 2A and 2B, which are directly linked to depression, in the brains of aged and ...
Source: Oncotarget - March 27, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

A commonly-used antidepressant doesn ' t improve recovery after stroke
The antidepressant fluoxetine works no better than placebo to reduce disability after a stroke, lowering hopes that had been raised by other smaller studies. After a six month trial including more than 3,000 adult stroke patients recruited at 103 UK hospitals, researchers concluded that fluoxetine should not be used to promote recovery from stroke-related disability, or routinely prescribed to prevent depression after stroke. Several smaller studies and animal trials had found promising results from the use of fluoxetine after stroke. However, this trial of fluoxetine 20mg daily for six months found no improvement in funct...
Source: Current Awareness Service for Health (CASH) - February 18, 2019 Category: Consumer Health News Source Type: news

Fluoxetine or Venlafaxine for Early Post Stroke Depression
Conclusions: PSD in the early phase affects a substantial number of the stroke patients. Venlafaxine has got a better outcome and adverse event profile compared to fluoxetine in this group of patients. However, larger multicenter studies will provide more helpful data in this area.
Source: Neurology India - December 19, 2022 Category: Neurology Authors: Vivek K Nambiar J Parvathy Tania M Philip K Abhijith S Sreeni Naveen K Panicker Amrutha V Ajai TS Dhanya Source Type: research

Neuroplasticity and behavioral effects of  fluoxetine after experimental stroke.
Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. Restor Neurol Neurosci. 2017 Aug 24;: Authors: Sun Y, Sun X, Qu H, Zhao S, Xiao T, Zhao C Abstract The brain can undergo self-repair and has the ability to compensate for functions lost after a stroke. The plasticity of the ischemic brain is influenced by several factors including aging and pharmacotherapy. Fluoxetine is an antidepressant which enhances serotonergic neurotransmission through selective inhibition of neuronal reuptake of serotonin. In clinical practice, fluoxetine alleviates the symptoms of post-stroke depre...
Source: Restorative Neurology and Neuroscience - September 1, 2017 Category: Neurology Tags: Restor Neurol Neurosci Source Type: research

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
CONCLUSIONS: There is high-quality evidence that SSRIs do not make a difference to disability or independence after stroke compared to placebo or usual care, reduced the risk of future depression, increased bone fractures and probably increased seizure risk.PMID:34780067 | DOI:10.1002/14651858.CD009286.pub4
Source: Cochrane Database of Systematic Reviews - November 15, 2021 Category: General Medicine Authors: Lynn A Legg Ann-Sofie Rudberg Xing Hua Simiao Wu Maree L Hackett Russel Tilney Linnea Lindgren Mansur A Kutlubaev Cheng-Fang Hsieh Amanda J Barugh Graeme J Hankey Erik Lundstr öm Martin Dennis Gillian E Mead Source Type: research

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial
Publication date: Available online 5 December 2018Source: The LancetAuthor(s): Martin Dennis, Gillian Mead, John Forbes, Catriona Graham, Maree Hackett, Graeme J Hankey, Allan House, Stephanie Lewis, Erik Lundström, Peter Sandercock, Karen Innes, Carol Williams, Jonathan Drever, Aileen Mcgrath, Ann Deary, Ruth Fraser, Rosemary Anderson, Pauli Walker, David Perry, Connor McgillSummaryBackgroundResults of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects.MethodsFOCUS was a pragmatic, multicentre, parallel group, double-b...
Source: The Lancet - December 5, 2018 Category: General Medicine Source Type: research

Treatments for Poststroke Motor Deficits and Mood Disorders: A Systematic Review for the 2019 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Stroke Rehabilitation.
Conclusion: Cardiorespiratory training, repetitive task training, and transcranial direct current stimulation may improve ADLs in adults with stroke. Cognitive behavioral therapy, exercise, and SSRIs may reduce symptoms of poststroke depression, but use of SSRIs to prevent depression or improve motor function was not supported. Primary Funding Source: U.S. Department of Veterans Affairs, Veterans Health Administration. PMID: 31739315 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - November 18, 2019 Category: Internal Medicine Authors: D'Anci KE, Uhl S, Oristaglio J, Sullivan N, Tsou AY Tags: Ann Intern Med Source Type: research

Is Fluoxetine Good for Subacute Stroke? A Meta-Analysis Evidenced From Randomized Controlled Trials
Conclusion: In post-stroke treatment, fluoxetine did not improve participants' mRS and NIHSS but improved FMMS and BI. This difference could result from heterogeneities between the trials: different treatment duration, clinical scales sensitivity, patient age, delay of inclusion, and severity of the deficit.
Source: Frontiers in Neurology - March 22, 2021 Category: Neurology Source Type: research

Does the Initiation of Fluoxetine Postacute Stroke Result in Improved Functional Recovery?: A Critically Appraised Topic
Conclusion: Among patients with stroke, early initiation of fluoxetine did not result in improved functional recovery. Lower rates of depression were observed in the fluoxetine-treated group; however these patients experienced higher rates of bone fracture.
Source: The Neurologist - May 1, 2021 Category: Neurology Tags: Critically Appraised Topics Source Type: research